-
Zealand Pharma Announces Positive Phase 2 ZUPREME-2 Topline Results for Amylin Analog Petrelintide in People with Overweight or Obesity and Type 2 Diabetes
NASDAQ: $ZEAL Copenhagen, Denmark, October 7, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced positive topline results from the Phase 2 ZUPREME-2 trial… Source: Read More
-
A Breakthrough in Weight Management: Corbus Pharmaceuticals Reports Positive Data for CRB-913
NASDAQ: $CRBP Promising Developments in Obesity Treatment The landscape of weight management is evolving rapidly, and a recent announcement from Corbus Pharmaceuticals has caught the attention of the medical community. The company has officially released positive topline data from their CANYON-1 study, which evaluated their daily oral candidate, CRB-913. Understanding the CANYON-1 Study The CANYON-1…
-
CagriSema vs. Tirzepatide: Insights from the REIMAGINE 5 Trial
A New Frontier in Weight Management The landscape of obesity treatment is evolving rapidly, and recent data from the REIMAGINE 5 trial has provided a compelling look at the next generation of weight-loss therapies. Novo Nordisk has shared results comparing their investigational drug, CagriSema, directly against tirzepatide (marketed as Zepbound/Mounjaro), marking a significant milestone in…
-
A New Horizon in Metabolic Health: Understanding Lilly’s Retatrutide
NYSE: $LLY A Breakthrough in Weight Loss and Diabetes Management Eli Lilly and Company has recently unveiled promising clinical trial results for their investigational molecule, retatrutide, a GGG triple hormone receptor agonist. This compound represents a significant leap forward in the treatment of obesity and type 2 diabetes by targeting three distinct pathways simultaneously. Understanding…
-
A New Frontier in Weight Management: AbbVie’s ABBV-295 Shows Promise
NYSE: $ABBV The Quest for Next-Generation Obesity Treatments As the landscape of metabolic medicine continues to evolve, AbbVie has recently stepped into the spotlight with promising new data from its clinical development program. The company has officially shared detailed Phase 1 results for ABBV-295, an experimental, long-acting amylin analog designed to address the complex needs…
-
CagriSema: The Breakthrough Combo Targeting ‘Food Noise’ and Metabolic Health
A New Frontier in Weight Management Recent clinical updates regarding CagriSema, an investigational drug developed by Novo Nordisk, are generating significant buzz in the medical community. This once-weekly injectable treatment combines semaglutide with cagrilintide, offering a dual-action approach to treating obesity and type 2 diabetes. Silencing ‘Food Noise’ One of the most compelling aspects of…
-
Boehringer Ingelheim’s Survodutide Achieves up to 13.1% Weight Loss in New Phase III Trial, Alongside Significant Improvements in Glycemic Control in People with Obesity and Type 2 Diabetes
Ingelheim, Germany, October 1, 2026 — Boehringer Ingelheim today announced positive results from the Phase III SYNCHRONIZE-2 trial, which investigates the glucagon/GLP-1 receptor dual agonist survodutide (BI 456906) in adults living with… Source: Read More
-
Breakthrough Study: Wegovy Shows Promise in Reducing Liver Fat
A Significant Shift in Obesity Treatment Recent clinical trial data has shed light on a potential new benefit for semaglutide (marketed as Wegovy). According to findings released by Novo Nordisk, the medication has demonstrated a remarkable ability to reduce liver fat in adults living with obesity and excess liver fat. The Findings at a Glance…
-
Could Zepbound Be the Key to Lower Healthcare Costs for Adults Over 55?
NYSE: $LLY New Real-World Data on Obesity Management A recent observational study has shed new light on the long-term impact of Zepbound (tirzepatide) on healthcare economics. While the medication is widely recognized for its efficacy in weight management, new data suggests that for adults over the age of 55, it may lead to significant reductions…